Laura S Gold1, Donald L Patrick2, Ryan N Hansen3, Valeria Beckett4, Christopher H Goss5, Larry Kessler6. 1. Department of Radiology, University of Washington, Seattle, WA, United States. Electronic address: goldl@uw.edu. 2. Department of Health Services, University of Washington, Seattle, WA, United States. Electronic address: donald@uw.edu. 3. School of Pharmacy, University of Washington, Seattle, WA, United States. Electronic address: rhansen@uw.edu. 4. Seattle Children's Research Institute, Seattle, WA, United States. Electronic address: Valeria.Beckett@seattlechildrens.org. 5. Departments of Medicine and Pediatrics, University of Washington, Seattle, WA, United States. Electronic address: goss@uw.edu. 6. Department of Health Services, University of Washington, Seattle, WA, United States. Electronic address: kesslerl@uw.edu.
Abstract
BACKGROUND: Pulmonary exacerbations (PEx) in cystic fibrosis (CF) patients decrease lung function, increase symptoms and reduce health-related quality of life (HRQoL). We evaluated associations between 8 symptom-based questions from the Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) and the 5-level EuroQOL-5 Dimensions (EQ-5D-5 L) summary score and hypothesized the CFRSD-CRISS would be well-correlated with quality-of-life measures among CF patients with PEx. METHODS: CF patients who had CFRSD-CRISS and EQ-5D-5L measurements on the day of the initial PEx, 7 days later, and at the end of intravenous antibiotic treatment were included. We examined age-stratified (<18 versus ≥18 years old) characteristics, including the percent predicted of forced expiratory volume in 1 s (ppFEV1), CFRSD-CRISS measurements, and domains of the EQ-5D. We also calculated age-stratified Pearson correlation coefficients between the EQ-5D-5L and CFRSD-CRISS items at each of the 3 time points. RESULTS: A total of 169 patients were analyzed. Patients reported having problems performing usual activities and with pain/discomfort on the first day of the PEx and these measures improved by the end of treatment. PpFEV1 improved in both age categories by the end of PEx treatment but was not associated with the change in summary EQ-5D-5 L over the time of PEx treatment (r-squared = 0.029). Correlations were weak (generally <0.4) between the elements of the EQ-5D-5 L versus the CFRSD-CRISS. CONCLUSIONS: Value assessment of treatments for CF PEx will require the collection of preference-weighted measures rather than only the symptom-based questions of the CFRSD-CRISS.
BACKGROUND: Pulmonary exacerbations (PEx) in cystic fibrosis (CF) patients decrease lung function, increase symptoms and reduce health-related quality of life (HRQoL). We evaluated associations between 8 symptom-based questions from the Cystic Fibrosis Respiratory Symptom Diary - Chronic Respiratory Infection Symptom Score (CFRSD-CRISS) and the 5-level EuroQOL-5 Dimensions (EQ-5D-5 L) summary score and hypothesized the CFRSD-CRISS would be well-correlated with quality-of-life measures among CFpatients with PEx. METHODS:CFpatients who had CFRSD-CRISS and EQ-5D-5L measurements on the day of the initial PEx, 7 days later, and at the end of intravenous antibiotic treatment were included. We examined age-stratified (<18 versus ≥18 years old) characteristics, including the percent predicted of forced expiratory volume in 1 s (ppFEV1), CFRSD-CRISS measurements, and domains of the EQ-5D. We also calculated age-stratified Pearson correlation coefficients between the EQ-5D-5L and CFRSD-CRISS items at each of the 3 time points. RESULTS: A total of 169 patients were analyzed. Patients reported having problems performing usual activities and with pain/discomfort on the first day of the PEx and these measures improved by the end of treatment. PpFEV1 improved in both age categories by the end of PEx treatment but was not associated with the change in summary EQ-5D-5 L over the time of PEx treatment (r-squared = 0.029). Correlations were weak (generally <0.4) between the elements of the EQ-5D-5 L versus the CFRSD-CRISS. CONCLUSIONS: Value assessment of treatments for CFPEx will require the collection of preference-weighted measures rather than only the symptom-based questions of the CFRSD-CRISS.
Authors: Christopher H Goss; Sonya L Heltshe; Natalie E West; Michelle Skalland; Don B Sanders; Raksha Jain; Tara L Barto; Barbra Fogarty; Bruce C Marshall; Donald R VanDevanter; Patrick A Flume Journal: Am J Respir Crit Care Med Date: 2021-12-01 Impact factor: 21.405
Authors: D R VanDevanter; S L Heltshe; D B Sanders; N E West; M Skalland; P A Flume; C H Goss Journal: J Cyst Fibros Date: 2020-08-13 Impact factor: 5.482
Authors: Natalie Franz; Hannah Rapp; Ryan N Hansen; Laura S Gold; Christopher H Goss; Noah Lechtzin; Larry G Kessler Journal: J Cyst Fibros Date: 2021-03-12 Impact factor: 5.482
Authors: Alex H Gifford; Deepika Polineni; Jianghua He; Jessica L D'Amico; Dana B Dorman; Molly A Williams; Amanda B Nymon; Akshu Balwan; Theodore Budden; Jonathan B Zuckerman Journal: Sci Rep Date: 2021-03-01 Impact factor: 4.379